DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report released on Thursday. The brokerage issued a hold rating on the stock.

Several other analysts have also recently weighed in on the stock. HC Wainwright increased their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $5.00 target price on shares of DBV Technologies in a research note on Tuesday, September 24th.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $0.59 on Thursday. DBV Technologies has a 1-year low of $0.50 and a 1-year high of $2.14. The stock has a market cap of $56.92 million, a P/E ratio of -0.66 and a beta of 0.66. The stock’s 50 day simple moving average is $0.72 and its 200-day simple moving average is $0.88.

DBV Technologies’s stock is set to reverse split on the morning of Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.